13 melanoma patients
Monocyte-derived and cocktail-matured DC electroporated with a combination of RNAs encoding tumor antigens (MelanA, Mage3, Survivin) and E/L-selectin are currently used in a clinical trial.
Most patients having received the vaccine already demonstrated broad responses to numerous peptides prior vaccination. Significantly enhanced responses to several peptides and occurrence of new responses was seen in 6 patients, 5 of which were vaccinated with E/L-S+ DC. These data provide evidence for a superior immunopotency of E/L-selectin expressing DC.
Biomaterial
Homo sapiens
Gerold Schuler
Gosse Adema
Carl Figdor
Alexander Steinkasserer
Melan A
melanoma antigen MAGE-3
survivin
selectin
DERMA-ER-DC 06 trial: RNA-based DC vaccine